The Bioptamers Platform
The Bioptamers platform is a proprietary technology for identifying highly specific aptamers that function as targeting agents, called "bioptamers". Using a patented microfluidics-enabled evolution process based on Systematic Evolution of Ligands by Exponential Enrichment (SELEX), the platform yields bioptamers with increased specificity for cancer cells.
About aptamersInternal Pipeline
Personalized Targeted Radiotheranostics
Bioptamers is developing personalized, cutting-edge targeted radiotheranostics to improve the precision of localization and therapeutic delivery to patients' cancer cells. Personalized targeting based on bioptamers comprises a first imaging step, followed by the targeted radiotherapy.